12.2 C
New York
Monday, June 5, 2023

Is Fate Therapeutics Inc. (NASDAQ: FATE) The Best Stock To Invest In?

After Hours

It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. After-hours trades for Fate Therapeutics Inc. (FATE) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.10, or 1.98%, to $5.14. The Fate Therapeutics Inc. has recorded 39,244 volume in the after hours trading session. The stock was recently discussed on Yahoo Finance as it revealed that Fate Therapeutics Reports First Quarter 2023 Financial Results and Business Updates.

Unlock the Hottest Top 10 Penny Stocks Today! Discover Now

Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.

Gain Access to Top 10 Penny Stocks Now!.


Stocks Info

Fate Therapeutics Inc. is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $5.04 and fluctuated between $5.34 as its day high and $4.99 as its day low. The current market capitalization of Fate Therapeutics Inc. is $486.91M. A total of 2.28 million shares were traded on the day, compared to an average of 2.69M shares.

Insider Activity

Insider trades are also considered as indicators of how a stock will perform in the future, in addition to stock predictions. During the recent three months, FATE has seen 0 BUY and 2 SELL insider trades, representing the acquisition of 0 and the disposition of 2,532 shares. Over the last 12 months, there were 21 BUYs and 26 SELLs from insiders. Insiders purchased 371,309 shares during that period but sold 191,189.

In the most recent transaction, Redmile Group, LLC bought 256,639 shares of FATE for 6.18 per share on Apr 21. After the transaction, the Director now owns 13,135,758 company shares. In a previous transaction on Apr 20, Redmile Group, LLC bought 20,000 shares at 5.99 per share. FATE shares that Director owns now total 12,879,119.

Among the insiders who sold shares, Chu Yu-Waye disposed of 2,532 shares on Apr 18 at a per-share price of $6.57. This resulted in the Chief Medical Officer holding 140,676 shares of FATE after the transaction. In another insider transaction, Redmile Group, LLC bought 25,700 shares at $6.00 per share on Apr 14. Company shares held by the Director now total 12,859,119.

Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. According to analysts who have offered 12-month price targets for FATE in the last 3 months, the mean price target is $8.16 with high estimates of $16.00 and low estimates of $4.00. In terms of 52-week highs and lows, FATE has a high of $37.13 and a low of $4.02.

As of this writing, FATE has an earnings estimate of -$0.6 per share for the current quarter. EPS was calculated based on a consensus of 21 estimates, with a high estimate of -$0.34 per share and a lower estimate of -$0.89. The company reported an EPS of -$0.58 in the last quarter, which was 32.60% higher than expectations of -$0.86.

Balance Sheet Annually/Quarterly

As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. FATE’s latest balance sheet shows that the firm has $615.91M in Cash & Short Term Investments as of fiscal 2021. There were $114.82M in debt and $81.28M in liabilities at the time. Its Book Value Per Share was $4.87, while its Total Shareholder’s Equity was $678.84M.

Analysts Opinion

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for FATE is Buy with a score of 3.50.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles